because of pulmonary hypertensive crises, pulmonary thrombosis, or refractory right heart failure. 1) The risk probably increases with more elevated pulmonary pressures. However, even moderate forms of pulmonary vascular disease can worsen during pregnancy as a result of the decrease in systemic vascular resistance and overload of the right ventricle, and no safe cut-off value is known. If pregnancy occurs, termination used to be offered. 3) Therefore, it is important to discuss effective methods of birth control with women with PAH of child-bearing potential, although the preferred method is not clear. 4) Hwang et al. 5) and Min et al. 6) reported successful deliveries of pulmonary hypertension while using ❙ABSTRACT❙ Pregnant women with severe pulmonary arterial hypertension (PAH) have a high maternal mortality risk. Regardless of the PAH severity, the possibility of maternal death increases before and after childbirth. In general principle, if pregnancy happens, termination is the recommendation. Several case reports noted successful deliveries of pregnant women with PAH while using the drugs of anticoagulants, calcium channel blockers, prostaglandins, and phosphodiesterase V inhibitors.
Introduction
A high maternal mortality risk is reported (30% to 50% in older series and 17% to 33% in more recent papers) in patients with severe pulmonary arterial hypertension (PAH). 1, 2) Even more, neonatal survival rates are reported to be 87% to 89%. Maternal death occurs in the last trimester of pregnancy and in the first months after delivery calcium channel blockers, low molecular weight heparin administration and sildenafil, a phosphodiesterase type V inhibitor. However, we handled a pregnant woman of PAH diagnosed by transthorasic echocardiography (TTE) without any specific medications and termination. We report a case of the pregnant woman who had mild form of PAH and successfully delivered without any medications.
Case report
A previously healthy 31-year-old, at 35 weeks' gestational age gravida (G3, P1) patient was consulted from obsterics department for evaluating repetitive cesarean sectional operation risks about the surgery in the past.
She had a history of heart valve surgery at 6 years old and after the surgery there was no follow-up due to good progress. Five years ago, she had first uncomplicated pregnancy and delivered a newborn by cesarean section without significant problems. She denied previous hyper- The patient and baby did not reveal the specific cardiovascular symptoms during admissions and have been on outpatient observation for twenty months.
Discussion
Severe PAH in pregnancy is considered to a very serious condition due to high maternal mortality risks (30% to 50% in older series and 17% to 33% in more recent papers). 1, 2) The disease is characterized by increased vas- pregnancy is contraindicated in patients with PAH because of the high mortality rates. 7) During pregnancy, 30% to 50% increase in blood volume, and 50% increase in cardiac output due to a reduction in systemic vascular resistance is observed. 8) In pregnant patients with PAH, increased blood volume and cardiac output cannot be accommodated and may be fatal due to right heart failure. 9) Other physiologic changes include an increase in cardiac output during labor in patients receiving local anesthesia (pudendal block) and postpartum intravascular volume shifts resulting from blood loss or diuresis. These physiologic events place a great demand on the cardiovascular system, with the greatest incidence of mortality occurring during the first several postoperative days. 10) Therefore, maternal death may occur at the labor, delivery, and in postpartum period. It is reported to be as high as 30% to 50% due to these circulatory and hematologic changes. 2) Maternal deaths mostly occur during the first 10 days after delivery. Preterm delivery rate is about 50%. 11) Recognition of the elevated maternal-fetal mortality rate has led physicians to recommend effective contraception and, in the event of a pregnancy, early fetal termination. 12) The TTE and Swan-Ganz catheter through the right side of the heart provides pressure measurements for diagnosis of PAH. A mean pulmonary arterial pressure ≥ while its utility has not been demonstrated; therefore, it is rarely if ever indicated. 3) In addition, its use has not been associated with improved survival, 14) and there is an increased risk of thrombosis in these conditions. 15 11, 19, 20) The short half-life of these compounds require frequent administration, either by inhalation or continuous intravenous infusion. Nitric oxide and sildenafil, a phosphodiesterase type V inhibitor which is a degrading enzyme of the second nitric oxide messenger, have also been used successfully either as sole agents or as adjuncts to other medications during the intra-partum course. A small group of PAH patients respond to oral sildenafil treatment and its use in pregnancy is safe. 21) In Korea, some case reports described successful deliveries of women with PAH while using calcium channel blockers, low molecular weight heparin administration and sildenafil. 5, 6) A management guideline of PAH, not specified for pregnant women, suggests starting oral treatment for patients in the WHO functional classes II and III, and considering parenteral prostanoids in suitable patients in the class IV or those with poor prognostic markers in the class III. If response to treatment is suboptimal, switching or adding further drugs is suggested. 22) The mortality probably increases with more elevated PAH. However, even moderate forms of PAH can worsen during pregnancy and no safe cut-off value is known. 3) There is a substantial need for long-term observational studies evaluating the various treatments in terms of survival, side effects, quality of life, and costs.
Since no data are available from head-to-head comparisons of approved therapies, the choice of treatment will be dictated by clinical experience and the availability of drugs, as well as by patients' preferences. 18 diac filling pressure and systemic BP must be prevented during regional or general anesthesia. 23, 24) Epidural anesthesia must be accomplished carefully to minimize peripheral vasodilatation and deterioration of the hemodynamics. The patients are recommended keeping in hospital for two weeks postpartum for monitoring. 25) Although the mode of delivery for patients with pulmonary hypertension is controversial, cesarean delivery was planned for our patient due to previous cesarean delivery.
Our patient safely delivered a newborn with the planned cesarean section under spinal anesthesia. Regional anesthesia to control pain and to avoid pain-related tachy- 1, 2) In this case, the newborn's Apgar scores and physical examination outcomes were favorable.
In summary, the PAH is a rare disease which afflicts young women of child bearing age. And the disease is associated with high maternal mortality and morbidity risks. Despite significant progress on comprehending the pathophysiology of PAH, no practical management guidelines for PAH in pregnancy are available to date.
Although women with severe PAH seem to be at higher risks, a safe cut-off value is not known. Anticoagulants, calcium channel blockers, prostaglandins, and phosphodiesterase V inhibitors as well as termination used to be empirically selected for PAH in pregnancy. We report a pregnant woman who was diagnosed as PAH by TTE at 
